Estimated Vaccination Coverage*,† among Adolescents Aged 13-17 Years§, by Race/ethnicity¶ for Selected Vaccines -- National Immunization Survey-Teen, United States, 2009
Vaccines  White only,
non-Hispanic
% (95% CI)
Black only,
non-Hispanic
% (95% CI)
Hispanic
% (95% CI)
American Indian or Alaska Native only,
non-Hispanic
% (95% CI)
Asian only,
non-Hispanic
% (95% CI)
>2 MMR**90.2 (89.3-91.1)86.3 (83.6-88.5)87.6 (84.9-89.9)90.4 (84.1-94.3)92.9 (88.5-95.8)
> 3 HepB††90.2 (89.4-91.0)88.9 (86.7-90.8)90.0 (87.7-91.9)89.7 (83.2-93.9)89.5 (83.3-93.6)
Varicella
History of varicella disease§§55.0 (53.5-56.4)49.0 (45.6-52.4)50.1 (46.3-53.9)52.3 (42.2-62.3)40.2 (31.7-49.4)
Among adolescents without history of disease:
>1 dose vaccine88.5 (87.0-89.8)82.4 (78.7-85.7)85.5 (81.1-89.0)87.9 (76.4-94.2)88.1 (79.9-93.2)
>2 dose vaccine48.8 (46.5-51.2)43.9 (39.2-48.6)49.7 (44.0-55.5)41.0 (26.6-57.1)54.2 (41.9-66.0)
History of disease or received =2 doses varicella vaccination¶¶77.0 (75.7-78.2)71.3 (68.2-74.3)74.9 (71.4-78.1)71.9 (60.3-81.1)72.6 (63.7-80.1)
Td or Tdap since age 10 years***
>1 dose Td or Tdap76.5 (75.4-77.7)72.5 (69.4-75.5)76.7 (73.2-79.9)78.0 (66.8-86.2)84.5 (77.1-89.8)
>1 dose Tdap55.8 (54.3-57.2)52.7 (49.3-56.1)55.6 (51.8-59.4)59.3 (48.8-69.1)64.3 (55.5-72.3)
MenACWY 1 dose†††53.1 (51.7-54.5)53.0 (49.6-56.4)55.9 (52.0-59.7)46.9 (37.3-56.8)58.8 (49.6-67.4)
HPV§§§
>1 dose 43.9 (41.8-46.1)44.6 (39.9-49.5)45.5 (40.3-50.8)52.3 (39.0-65.2)41.5 (29.5-54.5)
>3 doses29.1 (27.3-31.0)23.1 (19.1-27.6)23.4 (19.7-27.6)29.6 (20.1-41.4)22.1 (14.7-31.8)

 
* Estimate presented as point estimate (%) ± 95% confidence interval (CI). Estimate=NA (Not Available) if the unweighted sample size for the denominator
was <30 or (CI half width)/Estimate > 0.6.
† Estimates with confidence intervals >20 may not be reliable.
§ Adolescents in the 2009 NIS-Teen were born during January 1991-February 1997.
Vaccination coverage estimates include only adolescents who had adequately complete provider-reported immunization records.
National estimates do not include adolescents living in the U.S. Virgin Islands (i.e., St. Croix, St. Thomas, St. John, and Water Island) (n=333).
¶ Reported by respondent. Adolescents of Hispanic ethnicity may be of any race.
Native Hawaiian or other Pacific Islanders and persons of multiple races were not included because of small sample sizes
** > 2 doses of measles-mumps-rubella vaccine.
†† >3 doses of hepatitis B vaccine.
§§By parent/guardian report or provider records.
¶¶ Prior tables reported "history of disease or received =1 dose varicella vaccination." We now report "history of disease or received =2 doses varicella vaccination"
to follow current Advisory Committee of Immunization Practices guidelines for adequate protection against varicella infection.
*** > 1 dose of tetanus toxoid-diphtheria vaccine (Td) or tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) since the age of ten years.
††† >1 meningococcal conjugate vaccine or meningococcal -unknown type vaccine.
§§§ >1 human papillomavirus vaccine, either quadrivalent or bivalent. Percentages reported among females only.
tab15_race_nat